An observational study in Melanoma, sponsored by University Medical Center Groningen. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by University Medical Center Groningen · Observational
A retrospective study investigating the relationship between FDG-PET uptake and LDH levels.
Patient characteristics, tumour characteristics including the BRAF mutation status and baseline serum S100B and LDH levels of each patient will be retrospectively determined from the electronical patient file. In each patient, tumour burden and 18F-FDG uptake of the tumour lesions will be measured using multiple standard quantification parameters of the baseline 18F-FDG-PET scan. Tumour burden will also be measured on the baseline contrast enhanced CT scan. The correlation of each FDG-PET parameter with baseline LDH and S100B levels, respectively, will be analyzed using univariate and multivariate regression analysis.
3,073 studies on the registry are indexed under Melanoma; 529 are open to participants now.
This study's enrollment of 65 is below the median of 182 across 448 observational studies indexed under Melanoma.
Browse Melanoma studies →University Medical Center Groningen is the lead sponsor of 625 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with metastatic melanoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
Exclusion Criteria:
All patients \>18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
Independent correlation between baseline serum LDH level and 18F-FDG uptake of tumour lesions
Time frame: 3 months
Correlation between baseline serum LDH level and tumour 18F-FDG uptake in subgroups separated by metastasis site
Time frame: 3 months
Correlation between baseline serum S100B level and tumour 18F-FDG uptake
Time frame: 3 months
Difference between tumour burden as measured on CT scan and on 18F-FDG-PET
Time frame: 3 months
Difference between tumour volume as determined by manual measurement or semiautomatic measurement
Time frame: 3 months
Correlation of baseline serum LDH level with tumour volume as measured on CT scan and as measured on 18F-FDG-PET scan
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2016 to primary completion in Apr 2017, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →